Protocol Ledger

NCT07449936 · Phase III · ACTIVE NOT RECRUITING

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Interventional Phase III clinical trial protocol NCT07449936 sponsored by EyePoint Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-16 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07449936
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07449936
Protocol FieldVerified Registry Value
NCT IdentifierNCT07449936
Consolidated Lead SponsorEyePoint Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2026-02-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07449936
Hospital Research SiteLocationSite Profile
California Retina ConsultantsBakersfield, CAOpen Hospital Dossier ->
The Retina PartnersEncino, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI